New research asserts that Prescient is deeply undervalued
Pitt Street Research has released an equity valuation report on clinical stage oncology company Prescient...
Pitt Street Research has released an equity valuation report on clinical stage oncology company Prescient...
Prescient Therapeutics (ASX: PTX) reported encouraging results in several key targeted and cell therapies in...
Prescient Therapeutics (ASX: PTX) has been invited to present clinical data at the prestigious American...
Prescient Therapeutics (ASX: PTX) had a solid FY23 that has set the stage for a...
Clinical stage oncology company Prescient Therapeutics Ltd (ASX: PTX) has finished off another strong quarter...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed highly experienced US biotech executive...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has just presented at the Cell &...
Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation...
Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.